FNY Managed Accounts’s BioMarin Pharmaceuticals BMRN Stock Holding History

FNY Managed Accounts’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-500	Closed	-$45.2K	–	362
2014 Q4	$45.2K	Buy	+500	New	+$41.6K	0.05%	126

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FNY Managed Accounts's BMRN Position: Q1 2015 in Review

FNY Managed Accounts sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 500 shares — an estimated $45.2K sold.

FNY Managed Accounts first reported a position in BMRN in Q4 2014 and held it in 1 quarter. The position peaked at $45.2K in Q4 2014. 377 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

FNY Managed Accounts reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
FNY Managed Accounts sold 500 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $45.2K.
FNY Managed Accounts first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 1 quarter.
FNY Managed Accounts's BioMarin Pharmaceuticals position peaked at $45.2K in Q4 2014.
377 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on FNY Managed Accounts's 13F filing for Q1 2015, filed 6 May 2015.